Diabetic nephropathy results from prolonged hyperglycemia that initiates a cascade of damaging processes. Reactive oxygen species accumulate when excess glucose raises mitochondrial NADH and FADH2 flux, disrupting ATP synthesis and creating oxidative stress that damages proteins, lipids, and DNA. The review authors described how oxidative stress activates NF‑κB, PKC, TGF‑β1/Smad, and MAPK signaling, which suppress matrix metalloproteinases and promote extracellular matrix accumulation and glomerulosclerosis. Advanced glycation end products (AGEs) and their receptor RAGE produce distinct pathological responses in DN, including enhanced cytokine production and altered extracellular proteins; podocytes, mesangial cells, and glomerular endothelial cells show increased RAGE expression in disease models. Innate immune activation and elevated proinflammatory cytokines—IL‑1, IL‑6, IL‑18, and TNF‑α—were reported repeatedly in the literature reviewed as contributors to microvascular injury. The renin–angiotensin–aldosterone system remains a central driver: angiotensin II induces efferent arteriolar constriction, increases ROS, and stimulates fibrogenic cytokines that accelerate tubular fibrosis and proteinuria.
The review cataloged multiple phytoconstituents associated with renal benefit in preclinical studies. Investigators reported nephroprotective effects from flavonoids, alkaloids, polyphenols, and terpenoids. Specific molecules called out by the authors include quercetin, rutin, curcumin, berberine, mangiferin, gallic acid, and thymoquinone. These agents have been attributed with antihyperglycemic actions, direct antioxidant activity, suppression of proinflammatory mediators, antiapoptotic effects on renal cells, and lipid‑lowering properties. The review emphasized that several phytochemicals modulate innate immune pathways and signaling nodes implicated in DN—NLRP3 inflammasome activity, NF‑κB‑dependent transcription, and TGF‑β1‑driven fibrogenesis—providing a mechanistic rationale for their nephroprotective observations in vitro and in vivo.
Authors screened seven databases and report that 257 articles formed the basis of their synthesis. Preclinical models—cellular assays and animal studies—constituted the majority of evidence demonstrating improved renal biomarkers, reduced oxidative stress markers, attenuation of inflammatory cytokines, and preservation of renal histology following treatment with plant extracts or isolated phytochemicals. The review also included a table summarizing available clinical trials of alternative therapies against DN; however, the authors noted that high‑quality clinical evidence remains limited. They stated that variability in study design, inconsistent endpoints, and lack of standardized preparations hinder definitive clinical interpretation. The data indicated potential for adjunctive benefit but stopped short of recommending clinical adoption without further, well‑designed human trials.
Contemporary disease‑modifying therapies for diabetic kidney disease extend beyond glycemic and blood pressure control. The review lists RAAS blockade, SGLT2 inhibitors, GLP‑1 receptor agonists, and the nonsteroidal mineralocorticoid receptor antagonist finerenone as current elements of DKD management. The authors observed mechanistic overlap between these agents and several phytoconstituents—specifically in pathways regulating inflammation, oxidative stress, and fibrosis—suggesting that plant compounds could provide complementary modulation when used alongside established therapies. The review made clear that this potential is for adjunctive application and did not propose replacement of evidence‑based pharmacotherapies.
The review enumerated barriers that constrain therapeutic translation of medicinal plants. Investigators reported wide variability in phytochemical composition across plant preparations and emphasized difficulties in standardizing extracts. Bioavailability concerns and unclear optimal dosing regimens were repeatedly noted. The authors flagged the risk of drug–herb interactions and the relative scarcity of adequately controlled clinical trials assessing renal outcomes as major gaps. They recommended rigorous clinical trials and improved pharmacological characterization to determine safety, effective dosing, and potential interactions with standard DKD medications. These research needs and methodological limitations were presented as explicit next steps rather than speculative statements.
Limitations acknowledged by the review itself include heterogeneity of included studies and the predominance of preclinical evidence. The authors called for focused clinical research to translate promising preclinical signals into reproducible clinical benefits for patients with diabetic nephropathy.